<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871231</url>
  </required_header>
  <id_info>
    <org_study_id>CL006</org_study_id>
    <nct_id>NCT03871231</nct_id>
  </id_info>
  <brief_title>Unpinning Termination Therapy for VT/VF</brief_title>
  <official_title>An International Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Unpinning Termination Therapy in Patients With VT/VF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardialen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genae</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Five Corners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardialen, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to develop a better method for stopping potentially lethal heart
      rhythms than currently available defibrillators. This new method, called Unpinning
      Termination Therapy (UPT), is hypothesized to be effective in stopping these dangerous heart
      rhythms at lower voltages and energy than current defibrillators. Consequently, UPT may
      improve survival, reduce patient pain from shocks, and lead to longer lasting and smaller
      implantable defibrillators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective single-arm feasibility study involving acute testing of UPT electrotherapy in
      subjects with VT/VF during clinically indicated ventricular tachycardia catheter ablation
      procedure or indicated implantable cardioverter defibrillator implant, upgrade, or
      replacement or new CRT-D implant or upgrade to CRT-D.

      The study involves up to two roll in subjects at each participating site followed by an UPT
      evaluation and refinement segment in which remaining subjects are enrolled until arrhythmia
      terminations from UPT delivery are reliably achieved. A prospective evaluation segment will
      be performed to compare UPT against SBS and ATP if sufficient subjects remain once reliable
      terminations from UPT are achieved.

      Subjects will be evaluated at the visits for the Clinically-Indicated Procedure per standard
      of care. A single follow-up at up to 30 days post-procedure is required to assess subjects
      for adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Non-randomized, non-blinded, prospective, single-arm, acute, early-feasibility study</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of UPT therapy</measure>
    <time_frame>Study procedure and 30 day post procedure</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of UPT therapy</measure>
    <time_frame>30 day post procedure</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parameters at which UPT terminates VT and VF</measure>
    <time_frame>Study procedure</time_frame>
    <description>Voltage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voltage at which UPT and endocardial single biphasic shock terminate VT/VF</measure>
    <time_frame>Study procedure</time_frame>
    <description>Voltage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voltage at which UPT and ATP terminate VT</measure>
    <time_frame>Study procedure</time_frame>
    <description>Voltage</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>Unpinning Termination Therapy Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Unpinning Termination Therapy</intervention_name>
    <description>The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.</description>
    <arm_group_label>Unpinning Termination Therapy Arm</arm_group_label>
    <other_name>Multi-pulse therapy</other_name>
    <other_name>Multi-stage therapy</other_name>
    <other_name>Multi-stage electrotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Life expectancy of 1 year or greater

          2. Male or female between 18 and 75 years of age

          3. Willing and able to comply with the study protocol, provide a written informed consent

          4. Indication for an endocardial VT catheter ablation for sustained, life-threatening
             monomorphic VT OR an indication for VF and ICD implant (de novo implant, replacement
             or upgrade) OR CRT-D (de novo implant, upgrade from ICD) with transvenous leads for
             the risk of or presence of VT and/or VF.

          5. Etiology of arrhythmia, or risk of arrhythmia being ischemic dilated cardiomyopathy or
             non-ischemic idiopathic dilated cardiomyopathy both with LVEF ≤ 35% and meeting local
             standard of care

          6. Medically stable at time of consent to undergo DFT testing performed under general
             anesthesia or conscious sedation as determined by the investigator

        Exclusion Criteria:

        The subject must not meet any of the following exclusion criteria:

          1. Medically unstable at time of study and unsafe to undergo DFT testing under general
             anesthesia or conscious sedation as determined by the investigator

          2. Hemodynamic instability as determined by the investigator

          3. AF or atrial flutter for ≥ 48 hours or unknown duration, and no anticoagulation for
             preceding 3 weeks and no preoperative transesophageal echocardiographic confirmation
             of the absence of RA and LA thrombus

          4. AF or atrial flutter for &lt;48 hours and no Preoperative transesophageal
             echocardiographic confirmation of the absence of RA and LA thrombus

          5. Presence of intracardiac thrombus

          6. Inability to pass catheters to heart due to vascular limitations

          7. Cardiovascular anatomical defects that would complicate placement of the lead or
             catheter required by the protocol, including congenital heart disease and cardiac vein
             anomalies as determined by the investigator

          8. Pregnancy confirmed by test within 7 days of procedure

          9. Pacemaker dependent

         10. The presence of a normally functioning left ventricular lead which is not planned for
             revision

         11. Presence of ventricular assist device, including Intra-aortic balloon pump

         12. Subjects requiring the use of I.V. inotropes and/or vasopressors for hemodynamic
             support in the 14 days prior to the study

         13. Prior VT catheter ablation with associated serious complication, such as hemodynamic
             compromise despite pressor agents, stroke, cardiac perforation, AC fistula,
             pneumothorax, sepsis

         14. Incessant VT/VF or VT/VF storm

         15. LVEF &lt; 20%

         16. New York Heart Association (NYHA) Class IV heart failure

         17. Planned epicardial VT ablation on the same day as the research study

         18. History of hyper-coagulable state that could increase risk of thromboembolic events

         19. History of hemodynamic compromise due to valvular heart disease requiring IV inotropes
             or other circulatory support.

         20. Unstable coronary artery disease as determined by the investigator

         21. Severe proximal three-vessel or left main coronary artery disease, without
             revascularization as determined by the investigators

         22. History of embolic stroke, Transient Ischemic Attack or other thromboembolic event in
             the past 6 months

         23. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,
             Congenital Heart Anomaly, Cardiac Amyloidosis, Genetic Cardiac Channelopathy or
             Cardiac Sarcoidosis.

         24. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned
             for up to 1 month after enrollment (other than the planned treatment procedure)

         25. Morbid obesity: BMI&gt;39 kg/m2

         26. Cognitive or mental health status that would interfere with study participation and
             proper informed consent

         27. Presence of mechanical tricuspid valve

         28. Active Endocarditis

         29. Ventricular arrhythmia etiology sarcoidosis

         30. Valvular ventricular tachycardia

         31. Previously implanted lead is under recall by manufacturer or evidence of lead failure
             as determined by the investigator

         32. End Stage Renal Disease on hemodialysis or peritoneal dialysis, or estimated
             glomerular filtration rate (eGFR) &lt;15 ml/min

         33. Right atrial or right ventricular lead implanted within 12 months prior to screening

         34. Any other medical condition which may affect the outcome of this study or safety of
             the subject as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harris Haqqani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Prince Charles Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Munneke, MS</last_name>
    <phone>6128049516</phone>
    <email>DMunneke@cardialen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Rasmussen, BA</last_name>
    <phone>7196596363</phone>
    <email>trasmussen@cardialen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricel Roxas, RN</last_name>
      <phone>+61 7 3139 5906</phone>
      <email>maricel.roxas@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Megan Mearns, RN</last_name>
      <phone>+61 7 3139 4711</phone>
      <email>megan.mearns@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Harrisi Haqqani, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Brumby</last_name>
      <phone>07 5687 4952</phone>
      <email>traceybrumby@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Robert Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Norwood</city>
        <state>South Australia</state>
        <zip>5067</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Lin</last_name>
      <phone>08 313 9012</phone>
      <email>Jun.lin@adekaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Prash Sanders, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary-Anne Austin</last_name>
      <phone>03 9594 4507</phone>
      <email>Maryanne.Austin@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Alison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.</citation>
    <PMID>24076284</PMID>
  </reference>
  <reference>
    <citation>Janardhan AH, Li W, Fedorov VV, Yeung M, Wallendorf MJ, Schuessler RB, Efimov IR. A novel low-energy electrotherapy that terminates ventricular tachycardia with lower energy than a biphasic shock when antitachycardia pacing fails. J Am Coll Cardiol. 2012 Dec 11;60(23):2393-8. doi: 10.1016/j.jacc.2012.08.1001. Epub 2012 Nov 7.</citation>
    <PMID>23141483</PMID>
  </reference>
  <reference>
    <citation>Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.</citation>
    <PMID>21980076</PMID>
  </reference>
  <reference>
    <citation>Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10.</citation>
    <PMID>16945810</PMID>
  </reference>
  <reference>
    <citation>Ripplinger CM, Krinsky VI, Nikolski VP, Efimov IR. Mechanisms of unpinning and termination of ventricular tachycardia. Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H184-92. Epub 2006 Feb 24.</citation>
    <PMID>16501014</PMID>
  </reference>
  <reference>
    <citation>Li W, Ripplinger CM, Lou Q, Efimov IR. Multiple monophasic shocks improve electrotherapy of ventricular tachycardia in a rabbit model of chronic infarction. Heart Rhythm. 2009 Jul;6(7):1020-7. doi: 10.1016/j.hrthm.2009.03.015. Epub 2009 Mar 11.</citation>
    <PMID>19560090</PMID>
  </reference>
  <reference>
    <citation>Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.</citation>
    <PMID>20969974</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Termination</keyword>
  <keyword>Unpinning</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

